Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Sponsor: Helwan University
Summary
The purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels.
Official title: Concurrent Goserelin During Chemotherapy for Ovarian Function Preservation in Premenopausal Breast Cancer: An Open-Label Randomized Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-06-01
Completion Date
2024-07-01
Last Updated
2026-08-11
Healthy Volunteers
No
Conditions
Interventions
Gonadotropin-releasing hormone agonist
Patients received chemotherapy plus a gonadotropin-releasing hormone agonist.
Chemotherapy
Patients received chemotherapy alone.
Locations (1)
Helwan University
Helwan, Helwan, Egypt